Database release
Added entries:
- (FDA) ALK rearrangements and sensitivity to ensartinib for the treatment of adult patients with non-small cell lung cancer.
- (FDA) BRAF p.V600E and sensitivity to encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of patients with colorectal cancer.
- (FDA) KRAS p.G12C and sensitivity to panitumumab in combination with sotorasib for the treatment of adult patients with metastatic colorectal cancer.
Additionally, all records in the database now contain three additional keys: assertion_id, feature_id, and source_id, as they appear in the https://www.moalmanac.org/api/assertions endpoint. The assertion_id and feature_id values are simply the index value for each record in the database.
The https://www.moalmanac.org/api/features endpoint lists the unique features when not considering the feature_id key, and thus it returns a list of dictionaries containing the first instance of each genomic feature. This will be added at a later date to each record in molecular-oncology-almanac.json under the key features_endpoint_feature_id.